As the going gets tough for the country in the time of COVID-19, Telangana, one of the youngest States in India, is shouldering a major and crucial responsibility – ensuring adequate drugs to fight the pandemic.
Telangana, known as the ‘bulk drug capital of India’ accounts for 40 per cent of the total bulk drug production in the country and this is the time that the State is proving its worth in the sector. “We are leaving no stone unturned to improve supply of medicines to other States,” Telangana Drugs Control Administration Director Preeti Meena said.
“Telangana is the bulk drug capital of India as it accounts for 40 per cent of the total Indian bulk drug production. During the lockdown, most companies here have successfully supplied azithromycin and other anti-viral drugs used for treating COVID-19 patients in sufficient quantity without any hindrance,” Meena said, adding that the DCA was facilitating the bulk drug industries to conduct smooth production to meet the increasing requirements.